Madison, MISSISSIPPI5 Active Studies

Lung Cancer Clinical Trials in Madison, MISSISSIPPI

Find 5 actively recruiting lung cancer clinical trials in Madison, MISSISSIPPI. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
772
Enrolling

Recruiting Lung Cancer Studies in Madison

RecruitingMadison, MISSISSIPPINCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid...

497 participants
Apollomics Inc.
View Study Details
RecruitingMadison, MISSISSIPPINCT04367311

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high...

100 participants
Nasser Hanna
View Study Details
RecruitingMadison, MISSISSIPPINCT05742607

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in ...

70 participants
Innate Pharma
View Study Details
RecruitingMadison, MISSISSIPPINCT04919382

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metasta...

56 participants
Dwight Owen
View Study Details
RecruitingMadison, MISSISSIPPINCT05068232

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if ...

49 participants
University of Chicago
View Study Details

About Lung Cancer Clinical Trials in Madison

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 5 lung cancer clinical trials recruiting participants in Madison, MISSISSIPPI. These studies are seeking a combined 772 participants. Research is being sponsored by Apollomics Inc., Nasser Hanna, Innate Pharma and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Madison — FAQ

Are there lung cancer clinical trials in Madison?

Yes, there are 5 lung cancer clinical trials currently recruiting in Madison, MISSISSIPPI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Madison?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Madison research site will contact you about next steps.

Are clinical trials in Madison free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Madison studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 5 active trials in Madison are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov